Proc Natl Acad Sci U S A
December 2024
Background: The JYNNEOS vaccine (two doses given 28 days apart) was recommended in the United States for people at high risk of exposure to monkeypox virus during the 2022 mpox outbreak. Our objective was to assess the safety of JYNNEOS using two complementary epidemiologic methods.
Methods: This observational cohort included patients of eight large integrated healthcare organizations who received JYNNEOS.